Freenome pricing
No price is published by Freenome or Abbott. Abbott holds exclusive US commercial rights to SimpleScreen CRC ordered on its own and planned a fall 2026 launch, so it is the counterparty for the colorectal test alone; Freenome contracts directly with health systems for SimpleScreen Lung, a laboratory developed test, with SimpleScreen CRC and its digital tools. The company states that the approved colorectal test meets Medicare's coverage criteria. The partnership terms that are public (a $100 million milestone due on approval, further milestones and royalties) describe what Abbott pays Freenome, not a customer price.
How Freenome pricing works
- Pricing model
- Per test; SimpleScreen CRC sold by Abbott in the US, SimpleScreen Lung and CRC sold by Freenome to health systems through a Founding Partner program
Freenome pricing against its alternatives
Published prices for Freenome and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- FFreenomeNo published price
- GGRAIL$949 per test (list price)
- BbioAffinity TechnologiesNo published price
- GGuardant Health$1,495 Shield cash price per test
- VVeracyteNo published price
- CCaris Life SciencesNo published price
- WWaivNo published price
- DDoMore DiagnosticsNo published price
- SSamayNo published price
Freenome pricing, answered
How much does Freenome cost?
Freenome does not publish a price. Abbott holds exclusive US commercial rights to SimpleScreen CRC ordered on its own and planned a fall 2026 launch, so it is the counterparty for the colorectal test alone; Freenome contracts directly with health systems for SimpleScreen Lung, a laboratory developed test, with SimpleScreen CRC and its digital tools.